$Rig's Platinum Penny Alerts

[stervc]

BSSP Stage 3 Clinical Trials related Info:

This is huge news regarding BSSP and it new 100% Acquisition of Canteck Pharma, Inc. that all should read regarding the news, 8-K, and its Stage 3 Clinical Trials:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122173103

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122168792

This is a real business. Here is the website of one of the new directors-

http://www.immunotechlab.com/ipf/

Note the Stage 3 clinical trials in Europe.

Immunology, according to the Washington Post and the Economist is "changing the way we treat cancers".

https://www.washingtonpost.com/news/to-your-health/wp/2016/04/19/breakthrough-cancer-therapy-shows-growing-promise/

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122173103
BSSP Cancer Co. Acquisition News & 8-K

IPF for Cancer Treatment:
http://www.cantechpharma.com/cancer-treatment/


BSSP/Canteck Pharma, Inc. Patent:
http://www.google.com.na/patents/US8309072


http://finance.yahoo.com/news/reve-acquires-exclusive-license-cantecks-133000687.html

SAN CLEMENTE CA / ACCESSWIRE / April 25, 2016 / Reve Technologies, Inc. (BSSP) (the "Company" or "Reve") a development stage technology company is pleased to announce entered into a Purchase and Sale Agreement (the "Purchase Agreement") with Canteck Pharma, Inc., a Delaware corporation ("Canteck" or "CKPH") and certain majority shareholders of CKPH. Canteck has developed and patented technology (US 8,067,531 B2) known as Irreversible Pepsin Fraction ("IPF"). IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective.

The Purchase Agreement sets forth the plan through which the Company acquires One Hundred Percent (100%) ownership Interest in Canteck Pharma, Inc. for its current and planned operations in Mexico through the exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction specific to the Cancer indication only;

BSSP/Canteck Pharma 8-K filed with SEC:
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/0001594062-16-000450-index.htm

http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/form8k.htm

On April 19, 2016, Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) shares of the Company’s Common Restricted Stock were agreed to be issued to Canteck Pharma, Inc., representing 54.05% of the issued and outstanding shares of Common Stock, in behalf of the Purchase Agreement with Cantech. The shares shall have non dilutable provisions.

BSSP/Canteck Pharma Sales Agreement filed with the SEC:
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/ex101.htm

(A) Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) (the “Purchase Shares”) of REVE TECHNOLOGIES, INC.(“BSSP”) restricted common shares. The Purchase Shares are to carry a non-dilutable designation.

v/r
Sterling